Oral Solid Dosage Pharmaceutical Formulation Market Report 2026

Oral Solid Dosage Pharmaceutical Formulation Market Overview

• Oral Solid Dosage Pharmaceutical Formulation market size has reached to $653.26 billion in 2025 • Expected to grow to $846.38 billion in 2030 at a compound annual growth rate (CAGR) of 5.2% • Growth Driver: Chronic Disease Prevalence Drive Growth In The Oral Solid Dosage Pharmaceutical Formulation Market • Market Trend: Innovative Fixed‑Dose Combinations Aim To Boost Treatment Efficacy And Patient Compliance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oral Solid Dosage Pharmaceutical Formulation Market?

Oral solid dosage pharmaceutical formulation refers to a type of medication administered orally in a solid form. These formulations are designed to be swallowed and then dissolved or dispersed in the gastrointestinal tract, where the active pharmaceutical ingredients (APIs) are absorbed into the bloodstream to exert their therapeutic effects. Oral solid dosage pharmaceutical formulations are a cornerstone of modern medicine, offering a reliable, convenient, and effective method for drug delivery. The main dosage forms of oral solid dosage pharmaceutical formulations are tablets, capsules, powders and granules, lozenges and pastilles, and gummies. Tablets refer to solid oral dosage forms made by compressing powdered active ingredients and excipients into a compact, easily ingestible form. Various mechanisms were included, such as controlled release, immediate release, and delayed release. These formulations are sold through various distribution channels, such as hospital pharmacies, retail pharmacies, drug stores, online pharmacies, and hypermarkets or supermarkets, and are used by several end-users, including large-size companies, medium- and small-size companies, and others.

What Is The Oral Solid Dosage Pharmaceutical Formulation Market Growth Forecast?

The oral solid dosage pharmaceutical formulation market size is expected to see strong growth in the next few years. It will grow to $846.38 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing demand for long-acting oral medications, rising focus on patient adherence and convenience, expansion of pharmaceutical outsourcing and CDMO services, growth in global generic drug production, innovation in excipients and formulation technologies. Major trends in the forecast period include rising adoption of controlled and modified-release dosage forms, growing demand for patient-friendly oral solid formats, expansion of generic and branded solid dosage manufacturing, increasing focus on high-bioavailability formulations, shift toward cost-optimized and scalable oral dosage production.

What Is The Driver Of The Oral Solid Dosage Pharmaceutical Formulation Market?

The increasing prevalence of chronic diseases is expected to propel the growth of the oral solid dosage pharmaceutical formulation market going forward. Chronic diseases refer to long-term health conditions that persist for an extended period, typically lasting for three months or more. Chronic diseases are rising due to factors such as aging populations, sedentary lifestyles, poor dietary habits, environmental factors, and improved detection and diagnosis methods. Oral solid dosage pharmaceutical formulations are integral to chronic disease management and support long-term treatment adherence, as they are convenient, stable, and precise dosing. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, over 35 million new cancer cases were projected by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of chronic diseases drives the growth of the oral solid dosage pharmaceutical formulation industry.

Key Players In The Global Oral Solid Dosage Pharmaceutical Formulation Market

Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International

Global Oral Solid Dosage Pharmaceutical Formulation Market Trends and Insights

Major companies in the Oral Solid Dosage (OSD) pharmaceutical market are focusing on developing innovative solutions such as fixed dose combinations to enhance efficacy, patient compliance, and safety. A fixed dose combination (FDC) is a medication that contains two or more active drugs combined in a single dosage form to simplify treatment and improve patient adherence. For instance, in February 2025, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Journavex (suzetrigine) 50 mg oral tablets to treat moderate to severe acute pain in adults. It works by selectively inhibiting NaV1.8 sodium channels in the peripheral nervous system, blocking pain signals before they reach the brain, offering effective pain relief without addiction risks. Clinical trials demonstrated significant pain reduction compared to placebo, with a well-tolerated safety profile including mild side effects such as itching and muscle spasms.

What Are Latest Mergers And Acquisitions In The Oral Solid Dosage Pharmaceutical Formulation Market?

In March 2024, Roquette Frères, a France-based food company, acquired IFF Pharma Solutions for $2.85 billion. With this acquisition, Roquette solidifies its position in the pharmaceutical industry, expands its product range, enhances formulation capabilities, and strengthens its global presence, becoming a key player in innovative drug delivery solutions. IFF Pharma Solutions is a US-based company that provides pharmaceutical solutions, including tablets and capsules.

What Defines the Oral Solid Dosage Pharmaceutical Formulation Market?

The oral solid dosage pharmaceutical formulation market consists of sales of chewable tablets, multivitamin tablets, aspirin tablets, probiotic capsules, and protein powders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oral Solid Dosage Pharmaceutical Formulation Market Report 2026?

The oral solid dosage pharmaceutical formulation market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oral solid dosage pharmaceutical formulation industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.